MUC16 and cancer: Similarly, if the WHO response criteria underestimate a true benefit of an antineoplastic regimen in terms of a reduction in the number of CA125-expressing cancer cells as reflected by a CA125 response, a potential active regimen may be prematurely withdrawn in preference to supportive care.